Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors have revolutionized treatment for advanced high-grade serous ovarian cancer, especially in BRCA-mutated cases.
• Despite successes, limitations like resistance mechanisms and optimal patient selection persist, necessitating further research.
• Increasing use of PARP inhibitors in earlier treatment settings heightens concerns about de novo and acquired resistance.

Purpose of the Study:

• To review the current landscape of PARP inhibitors in ovarian cancer management.
• To explore emerging resistance mechanisms to PARP inhibitors.
• To discuss the rationale and potential of novel PARP inhibitor combinations.

Main Methods:

• Literature review of preclinical and clinical studies on PARP inhibitors in ovarian cancer.
• Analysis of resistance mechanisms, including genetic and epigenetic factors.
• Evaluation of ongoing and proposed clinical trials investigating PARP inhibitor combinations.

Main Results:

• PARP inhibitors demonstrate significant efficacy, particularly in BRCA-mutated ovarian cancer.
• De novo and acquired resistance are significant clinical challenges.
• Combination strategies are being explored to enhance efficacy and overcome resistance.

Conclusions:

• PARP inhibitors remain a cornerstone in ovarian cancer therapy, but resistance necessitates innovative approaches.
• Further investigation into patient selection and combination therapies is crucial for optimizing outcomes.
• Understanding resistance mechanisms will guide the development of next-generation PARP inhibitor strategies.